PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer.

Amante, Romain J; Jehanno, Charly; De Silva, Duvini; Coissieux, Marie-May; Ackerknecht, Markus; Romanet, Vincent; Sethi, Atul; Hamelin, Baptiste; Preca, Bogdan-Tiberius; Piscuoglio, Salvatore; Ng, Charlotte K Y; Mohseni, Morvarid; Bentires-Alj, Mohamed (2023). PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer. Journal of mammary gland biology and neoplasia, 28(1), p. 13. Springer 10.1007/s10911-023-09539-9

[img]
Preview
Text
s10911-023-09539-9.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

The protein tyrosine phosphatase SHP2 activates oncogenic pathways downstream of most receptor tyrosine kinases (RTK) and has been implicated in various cancer types, including the highly aggressive subtype of triple-negative breast cancer (TNBC). Although allosteric inhibitors of SHP2 have been developed and are currently being evaluated in clinical trials, neither the mechanisms of the resistance to these agents, nor the means to circumvent such resistance have been clearly defined. The PI3K signaling pathway is also hyperactivated in breast cancer and contributes to resistance to anticancer therapies. When PI3K is inhibited, resistance also develops for example via activation of RTKs. We therefore assessed the effect of targeting PI3K and SHP2 alone or in combination in preclinical models of metastatic TNBC. In addition to the beneficial inhibitory effects of SHP2 alone, dual PI3K/SHP2 treatment decreased primary tumor growth synergistically, blocked the formation of lung metastases, and increased survival in preclinical models. Mechanistically, transcriptome and phospho-proteome analyses revealed that resistance to SHP2 inhibition is mediated by PDGFRβ-evoked activation of PI3K signaling. Altogether, our data provide a rationale for co-targeting of SHP2 and PI3K in metastatic TNBC.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)

UniBE Contributor:

Ng, Kiu Yan Charlotte

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1573-7039

Publisher:

Springer

Language:

English

Submitter:

Pubmed Import

Date Deposited:

12 Jun 2023 12:47

Last Modified:

18 Jun 2023 02:21

Publisher DOI:

10.1007/s10911-023-09539-9

PubMed ID:

37294349

Uncontrolled Keywords:

Breast cancer Metastasis PDGFRβ PI3K SHP2

BORIS DOI:

10.48350/183295

URI:

https://boris.unibe.ch/id/eprint/183295

Actions (login required)

Edit item Edit item
Provide Feedback